{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:11:40Z","timestamp":1696324300941},"reference-count":11,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1272\/jnms.77.254","type":"journal-article","created":{"date-parts":[[2010,11,4]],"date-time":"2010-11-04T06:07:02Z","timestamp":1288850822000},"page":"254-259","source":"Crossref","is-referenced-by-count":2,"title":["Stem Cell Transplantation Using Non-myeloablative Conditioning Regimen with Fludarabine for Hematological Malignancies"],"prefix":"10.1272","volume":"77","author":[{"given":"Kenji","family":"Tajika","sequence":"first","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Mizuki","sequence":"additional","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Dan","sequence":"additional","affiliation":[{"name":"Department of Pathophysiological Management\/Medical Oncology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.","DOI":"10.1182\/blood.V91.3.756"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chae YS, Sohn SK, Kim JG, et al.: New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007; 40: 541-547.","DOI":"10.1038\/sj.bmt.1705770"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saito AM, Kami M, Mori S, et al.: Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007; 82: 873-880.","DOI":"10.1002\/ajh.20977"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sobecks RM, Dean R, Rybicki LA, et al.: 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42: 715-722.","DOI":"10.1038\/bmt.2008.248"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takahata M, Hashino S, Okada L, et al.: Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI) : Clinical efficacy in high-risk patients. Am J Hematol 2010; 84: 243-248.","DOI":"10.1002\/ajh.21630"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Valcárcel D, Martino R, Caballero D, et al.: Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.","DOI":"10.1200\/JCO.2007.11.1641"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Armand P, Kim HT, Ho VT, et al.: Allogeneic transplantation with reduced intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418-425.","DOI":"10.1016\/j.bbmt.2008.01.008"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cho BS, Lee S, Kim YJ, et al.: Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009; 23: 1763-1770.","DOI":"10.1038\/leu.2009.102"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shimoni A, Hardan I, Shem-Tov N, et al.: Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine\/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine\/busulfan. Leukemia 2007; 21: 2109-2116.","DOI":"10.1038\/sj.leu.2404886"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shimoni A, Hardan I, Shem-Tov N, et al.: Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007; 48: 2352-2359.","DOI":"10.1080\/10428190701671051"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Scott Baker K, DeFor TE, Burns LJ, et al.: New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.","DOI":"10.1200\/JCO.2003.05.108"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jnms\/77\/5\/77_5_254\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T07:42:30Z","timestamp":1617003750000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jnms\/77\/5\/77_5_254\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.77.254","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}